.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, individuals along with metastatic gastrointestinal lumps that obtained biomarker-matched therapies based on circulating growth DNA profiling showed a greater scientific perk than those getting unparalleled treatment.